Guselkumab is superior to fumaric acid esters in patients with moderate‐to‐severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active‐comparator‐controlled phase IIIb trial (POLARIS)

User: Guest

Title:: Guselkumab is superior to fumaric acid esters in patients with moderate‐to‐severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active‐comparator‐controlled phase IIIb trial (POLARIS)
Document type:: Zeitschriftenaufsatz
Author(s):: Thaçi, D.; Pinter, A.; Sebastian, M.; Termeer, C.; Sticherling, M.; Gerdes, S.; Wegner, S.; Krampe, S.; Bartz, H.; Rausch, C.; Mensch, A.; Eyerich, K.
Journal title:: British Journal of Dermatology
Year:: 2020
Fulltext / DOI:: doi:10.1111/bjd.18696
Publisher:: Wiley
E-ISSN:: 0007-09631365-2133
Date of publication:: 20.01.2020
BibTeX

Occurrences: